Safety, dosing, and pharmaceutical quality for studies that evaluate medicinal products (including biological products) in neonates.



Ward, Robert M, Benjamin, Daniel, Barrett, Jeffrey S, Allegaert, Karel ORCID: 0000-0001-9921-5105, Portman, Ronald, Davis, Jonathan M and Turner, Mark A ORCID: 0000-0002-5299-8656
(2017) Safety, dosing, and pharmaceutical quality for studies that evaluate medicinal products (including biological products) in neonates. Pediatric research, 81 (5). 692 - 711.

[img] Text
INC Clin Pharm White Paper Summary.docx - Accepted Version

Download (64kB)
[img] Text
table edited..docx - Accepted Version

Download (13kB)

Abstract

The study of medications among pediatric patients has increased worldwide since 1997 in response to new legislation and regulations, but these studies have not yet adequately addressed the therapeutic needs of neonates. Additionally, extant guidance developed by regulatory agencies worldwide does not fully address the specificities of neonatal drug development, especially among extremely premature newborns who currently survive. Consequently, an international consortium from Canada, Europe, Japan, and the United States was organized by the Critical Path Institute to address the content of guidance. This group included neonatologists, neonatal nurses, parents, regulators, ethicists, clinical pharmacologists, specialists in pharmacokinetics, specialists in clinical trials and pediatricians working in the pharmaceutical industry. This group has developed a comprehensive, referenced White Paper to guide neonatal clinical trials of medicines - particularly early phase studies. Key points include: the need to base product development on neonatal physiology and pharmacology while making the most of knowledge acquired in other settings; the central role of families in research; and the value of the whole neonatal team in the design, implementation and interpretation of studies. This White Paper should facilitate successful clinical trials of medicines in neonates by informing regulators, sponsors, and the neonatal community of existing good practice.

Item Type: Article
Uncontrolled Keywords: Humans, Biological Factors, Pharmaceutical Preparations, Risk Assessment, Risk Factors, Evidence-Based Medicine, Age Factors, Dose-Response Relationship, Drug, Research Design, Quality Control, Infant, Newborn, Clinical Trials as Topic, Drug Dosage Calculations
Depositing User: Symplectic Admin
Date Deposited: 01 Aug 2017 09:30
Last Modified: 28 May 2020 17:10
DOI: 10.1038/pr.2016.221
URI: http://livrepository.liverpool.ac.uk/id/eprint/3008701